KA/EN
Register
Medicines reference
Search
Search
Product

Express Uspocoin

Favourites

Trazodone · Scientific Innovative Enterprise Astrafarm Ltd

2 forms: scored tablet. In force in Georgia: 2 of 2 (veterinary register).

Forms and doses2 of 2 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
24 mg tablets, Scored tablet · Cat up to 2 kg Cat up to 2 kg Situational Anxiety · By mouth: 1/2 tablet - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
24 mg tablets, Scored tablet · Cat 2–4 kg Cat 2–4 kg Situational Anxiety · By mouth: 1 tablet - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
24 mg tablets, Scored tablet · Cat 4–6 kg Cat 4–6 kg Situational Anxiety · By mouth: 1 1/2 tablets - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
24 mg tablets, Scored tablet · Cat 6–8 kg Cat 6–8 kg Situational Anxiety · By mouth: 2 tablets - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
24 mg tablets, Scored tablet · Dog up to 2 kg Dog up to 2 kg Situational Anxiety · By mouth: 1/2 tablet - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
24 mg tablets, Scored tablet · Dog 2–4 kg Dog 2–4 kg Situational Anxiety · By mouth: 1 tablet - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
24 mg tablets, Scored tablet · Dog 4–6 kg Dog 4–6 kg Situational Anxiety · By mouth: 1 1/2 tablets - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
24 mg tablets, Scored tablet · Dog 6–9 kg Dog 6–9 kg Situational Anxiety · By mouth: 2 tablets - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
24 mg tablets, Scored tablet · Dog 9–12 kg Dog 9–12 kg Situational Anxiety · By mouth: 2 1/2 tablets - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
Details: pack, label wording, sources, registration

Express Uspocoin 24 mg tablets, Scored tablet

N2/N6 for cats and small dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Short-term situational fear and anxiety before a predictable stressor
6.1/10
Situational / acceptable
vetman assessment

Express Uspocoin

24 mg tablets, N2/N6 for cats and small dogs
Assessed clinical scopeDog · Short-term situational fear and anxiety before a predictable stressor · By mouth
Care settingVeterinarian-selected pre-event oral medication, integrated with low-stress handling and a behaviour plan
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · № 000166 | 000176 | 000177 · Verified on 23 Oct 2026

A practical exact small-dog presentation with credible class efficacy; coarse low-weight dosing and limited exact-formulation evidence keep it situational.

Regulatory and scientific credibility5.5/10

Exact current instruction and Georgian veterinary registrations verify identity, strengths, species and dose tables. Independent exact-formulation evidence and internationally recognised exact-product authorisation remain limited.

Clinical efficacy6.0/10

Randomised canine studies support trazodone for veterinary-visit and travel stress at broadly comparable active exposure, but the exact succinate formulation and every broad label scenario lack strong independent replication.

Safety and tolerability6.0/10

Canine single-dose evidence is reasonably reassuring, but sedation, ataxia and examination changes are expected possibilities; serotonergic, cardiovascular, seizure, organ-disease and reproductive restrictions remain clinically important.

Clinical practicality7.5/10

A palatable scored tablet and one pre-event dose are practical, but half-tablet steps create coarse exposure at low weights and food timing plus possible redosing require a written plan.

Full-course cost-effectiveness-

A current, presentation-specific Georgian full-course price comparison was not verified; cost is excluded from the denominator.

Important safety and use flags

  • Complete assessed role: short-term situational fear/anxiety around predictable transport, veterinary or grooming visits, loud events and separation. It is not a stand-alone treatment for chronic behavioural disease, aggression or an uninvestigated medical cause.
  • Dose by the exact current table 60 minutes before the stressor. The label permits a repeat only after 6-8 hours when needed; do not shorten the interval or turn episodic use into an unsupervised daily course.
  • Each tablet contains 24 mg trazodone succinate, equivalent to 18.24 mg trazodone—not 24 mg trazodone base. Use only label-supported half-tablet steps and weigh small patients accurately.
  • Give no later than 30 minutes before the main meal or 2-4 hours after it. Immediate post-meal administration delays the effect; record timing so apparent failure is not automatically redosed.
  • Do not use in pregnancy, lactation or neonates, or in patients with cardiovascular disease, epilepsy, clinically important liver/kidney dysfunction or known hypersensitivity, as specified by the exact instruction.
  • Expect possible drowsiness, impaired coordination or altered neurologic examination; paradoxical agitation can occur. Trial the plan when safe, prevent falls/escape and do not assume a sedated animal is anxiety-free.
  • Avoid monoamine oxidase inhibitors and review SSRIs/SNRIs/TCAs, tramadol, mirtazapine and other serotonergic medicines. Agitation, tremor, hyperthermia, diarrhoea, tachycardia or rigidity requires urgent assessment for serotonin toxicity.
  • Review CYP3A4 inhibitors/inducers, CNS depressants, antihypertensives and QT-prolonging medicines. Extra caution is required with hypotension, arrhythmia risk or concurrent procedural sedatives; the exact product lacks broad combination trials.
  • Pre-event medication complements low-stress handling, environmental control, desensitisation/counterconditioning and diagnosis of pain or disease. It must not be used simply to suppress defensive behaviour for a forced procedure.
  • Georgia lists the exact 24 mg and 120 mg veterinary presentations through 3 August 2027. This confirms Georgian registration, not FDA/EU/GB approval or equivalence to a trazodone-hydrochloride product.
Assessment sources
  1. Express Uspocoin exact label2023
  2. Express Uspocoin GE register2026
  3. EU Express Uspocoin market audit2026
  4. GB Express Uspocoin market audit2026
  5. FDA Express Uspocoin market audit2026
  6. Dog veterinary-visit RCT2022
  7. Dog road-travel trial2026
  8. Dog neurologic effects2022
  9. Dog QT study2025
  10. FDA trazodone veterinary status2025
  11. Trazodone class safety2026
  12. Cat veterinary-visit RCT2016
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Short-term situational fear and anxiety before a predictable stressor
5.6/10
Weak evidence support
vetman assessment

Express Uspocoin

24 mg tablets, N2/N6 for cats and small dogs
Assessed clinical scopeCat · Short-term situational fear and anxiety before a predictable stressor · By mouth
Care settingVeterinarian-selected pre-event oral medication, integrated with low-stress handling and a behaviour plan
vetman score 5.6/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, veterinary · № 000166 | 000176 | 000177 · Verified on 23 Oct 2026

A convenient exact feline presentation with a plausible trazodone effect, but limited and inconsistent independent feline evidence keeps it a cautious situational option.

Regulatory and scientific credibility5.5/10

Exact current instruction and Georgian veterinary registrations verify identity, strengths, species and dose tables. Independent exact-formulation evidence and internationally recognised exact-product authorisation remain limited.

Clinical efficacy4.5/10

A small feline crossover trial supports pre-visit trazodone, but a 2025 review judged the overall evidence weak; the exact succinate product relies mainly on sponsor-linked studies and its base-equivalent dose is below the best-known 50 mg trial in many cats.

Safety and tolerability5.5/10

Single-dose feline studies are generally reassuring but small; sedation, ataxia or paradoxical agitation remain possible, while exact-label exclusions cover cardiovascular disease, epilepsy, organ dysfunction, pregnancy, lactation and neonates.

Clinical practicality7.5/10

A palatable scored tablet and one pre-event dose are practical, but half-tablet steps create coarse exposure at low weights and food timing plus possible redosing require a written plan.

Full-course cost-effectiveness-

A current, presentation-specific Georgian full-course price comparison was not verified; cost is excluded from the denominator.

Important safety and use flags

  • Complete assessed role: short-term situational fear/anxiety around predictable transport, veterinary or grooming visits, loud events and separation. It is not a stand-alone treatment for chronic behavioural disease, aggression or an uninvestigated medical cause.
  • Dose by the exact current table 60 minutes before the stressor. The label permits a repeat only after 6-8 hours when needed; do not shorten the interval or turn episodic use into an unsupervised daily course.
  • Each tablet contains 24 mg trazodone succinate, equivalent to 18.24 mg trazodone—not 24 mg trazodone base. Use only label-supported half-tablet steps and weigh small patients accurately.
  • Give no later than 30 minutes before the main meal or 2-4 hours after it. Immediate post-meal administration delays the effect; record timing so apparent failure is not automatically redosed.
  • Do not use in pregnancy, lactation or neonates, or in patients with cardiovascular disease, epilepsy, clinically important liver/kidney dysfunction or known hypersensitivity, as specified by the exact instruction.
  • Expect possible drowsiness, impaired coordination or altered neurologic examination; paradoxical agitation can occur. Trial the plan when safe, prevent falls/escape and do not assume a sedated animal is anxiety-free.
  • Avoid monoamine oxidase inhibitors and review SSRIs/SNRIs/TCAs, tramadol, mirtazapine and other serotonergic medicines. Agitation, tremor, hyperthermia, diarrhoea, tachycardia or rigidity requires urgent assessment for serotonin toxicity.
  • Review CYP3A4 inhibitors/inducers, CNS depressants, antihypertensives and QT-prolonging medicines. Extra caution is required with hypotension, arrhythmia risk or concurrent procedural sedatives; the exact product lacks broad combination trials.
  • Pre-event medication complements low-stress handling, environmental control, desensitisation/counterconditioning and diagnosis of pain or disease. It must not be used simply to suppress defensive behaviour for a forced procedure.
  • Georgia lists the exact 24 mg and 120 mg veterinary presentations through 3 August 2027. This confirms Georgian registration, not FDA/EU/GB approval or equivalence to a trazodone-hydrochloride product.
Assessment sources
  1. Express Uspocoin exact label2023
  2. Express Uspocoin GE register2026
  3. EU Express Uspocoin market audit2026
  4. GB Express Uspocoin market audit2026
  5. FDA Express Uspocoin market audit2026
  6. Cat veterinary-visit RCT2016
  7. Cat trazodone evidence review2025
  8. Cat oral-sedation trial2024
  9. Cat cardiovascular study2025
  10. FDA trazodone veterinary status2025
  11. Trazodone class safety2026
  12. Dog veterinary-visit RCT2022
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Trazodone18.24 mg/tablet
Formulation Type
Scored tablet
Administration route
By mouth
Registration
Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000166 | 000176 | 000177
Verified on: 23 Oct 2026
 EU No
Verified on: 23 Oct 2026
 UK No
Verified on: 23 Oct 2026
 US No
Verified on: 23 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Cat
WeightSituational Anxiety · By mouth
up to 2 kg 1/2 tablet
2–4 kg 1 tablet
4–6 kg 1 1/2 tablets
6–8 kg 2 tablets
  • Situational Anxiety · By mouth (once 60 minutes before the stressor; may repeat after 6-8 hours if needed): Give on an empty stomach or at least 2-4 hours after food. Do not use with hypersensitivity, liver/kidney dysfunction, cardiovascular disease or epilepsy, in pregnancy/lactation, or in newborn kittens. Sedation and impaired coordination can occur; review serotonergic and CYP3A4 interactions.
Source:
Express Uspocoin label
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Express Uspocoin tablets - regulator-approved veterinary instruction
Rosselkhoznadzor-approved veterinary instruction, 2023
Dog
WeightSituational Anxiety · By mouth
up to 2 kg 1/2 tablet
2–4 kg 1 tablet
4–6 kg 1 1/2 tablets
6–9 kg 2 tablets
9–12 kg 2 1/2 tablets
  • Situational Anxiety · By mouth (once 60 minutes before the stressor; may repeat after 6-8 hours if needed): Give on an empty stomach or at least 2-4 hours after food. Do not use with hypersensitivity, liver/kidney dysfunction, cardiovascular disease or epilepsy, in pregnancy/lactation, or in newborn puppies. Sedation and impaired coordination can occur; review serotonergic and CYP3A4 interactions.
Source:
Express Uspocoin label
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Express Uspocoin tablets - regulator-approved veterinary instruction
Rosselkhoznadzor-approved veterinary instruction, 2023
120 mg tablets, Scored tablet · Dog 9–12 kg Dog 9–12 kg Situational Anxiety · By mouth: 1/2 tablet - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000165
Verified on: 23 Oct 2026
120 mg tablets, Scored tablet · Dog 12–21 kg Dog 12–21 kg Situational Anxiety · By mouth: 1 tablet - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000165
Verified on: 23 Oct 2026
120 mg tablets, Scored tablet · Dog 21–30 kg Dog 21–30 kg Situational Anxiety · By mouth: 1 1/2 tablets - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000165
Verified on: 23 Oct 2026
120 mg tablets, Scored tablet · Dog 30–40 kg Dog 30–40 kg Situational Anxiety · By mouth: 2 tablets - Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000165
Verified on: 23 Oct 2026
Details: pack, label wording, sources, registration

Express Uspocoin 120 mg tablets, Scored tablet

N6 for medium and large dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
6.2/10
Situational / acceptable
vetman assessment

Express Uspocoin

120 mg tablets, N6 for medium and large dogs
Assessed clinical scopeDog · Short-term situational fear and anxiety before a predictable stressor · By mouth
Care settingVeterinarian-selected pre-event oral medication, integrated with low-stress handling and a behaviour plan
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · № 000165 · Verified on 23 Oct 2026

A practical exact medium/large-dog presentation with credible class efficacy; product-specific independence and safety transparency keep it situational rather than first-tier.

Regulatory and scientific credibility5.5/10

Exact current instruction and Georgian veterinary registrations verify identity, strengths, species and dose tables. Independent exact-formulation evidence and internationally recognised exact-product authorisation remain limited.

Clinical efficacy6.0/10

Randomised canine studies support trazodone for veterinary-visit and travel stress at broadly comparable active exposure, but the exact succinate formulation and every broad label scenario lack strong independent replication.

Safety and tolerability6.0/10

Canine single-dose evidence is reasonably reassuring, but sedation, ataxia and examination changes are expected possibilities; serotonergic, cardiovascular, seizure, organ-disease and reproductive restrictions remain clinically important.

Clinical practicality8.0/10

One scored palatable tablet strength covers the label’s medium/large-dog bands and is given 60 minutes before the event; half-tablet steps and the over-40 kg rule still require exact weight-based selection.

Full-course cost-effectiveness-

A current, presentation-specific Georgian full-course price comparison was not verified; cost is excluded from the denominator.

Important safety and use flags

  • Complete assessed role: short-term situational fear/anxiety around predictable transport, veterinary or grooming visits, loud events and separation. It is not a stand-alone treatment for chronic behavioural disease, aggression or an uninvestigated medical cause.
  • Dose by the exact current table 60 minutes before the stressor. The label permits a repeat only after 6-8 hours when needed; do not shorten the interval or turn episodic use into an unsupervised daily course.
  • Each tablet contains 120 mg trazodone succinate, equivalent to 91.2 mg trazodone—not 120 mg trazodone base. Above 40 kg, follow the exact stepped label rule rather than extrapolating a continuous mg/kg formula.
  • Give no later than 30 minutes before the main meal or 2-4 hours after it. Immediate post-meal administration delays the effect; record timing so apparent failure is not automatically redosed.
  • Do not use in pregnancy, lactation or neonates, or in patients with cardiovascular disease, epilepsy, clinically important liver/kidney dysfunction or known hypersensitivity, as specified by the exact instruction.
  • Expect possible drowsiness, impaired coordination or altered neurologic examination; paradoxical agitation can occur. Trial the plan when safe, prevent falls/escape and do not assume a sedated animal is anxiety-free.
  • Avoid monoamine oxidase inhibitors and review SSRIs/SNRIs/TCAs, tramadol, mirtazapine and other serotonergic medicines. Agitation, tremor, hyperthermia, diarrhoea, tachycardia or rigidity requires urgent assessment for serotonin toxicity.
  • Review CYP3A4 inhibitors/inducers, CNS depressants, antihypertensives and QT-prolonging medicines. Extra caution is required with hypotension, arrhythmia risk or concurrent procedural sedatives; the exact product lacks broad combination trials.
  • Pre-event medication complements low-stress handling, environmental control, desensitisation/counterconditioning and diagnosis of pain or disease. It must not be used simply to suppress defensive behaviour for a forced procedure.
  • Georgia lists the exact 24 mg and 120 mg veterinary presentations through 3 August 2027. This confirms Georgian registration, not FDA/EU/GB approval or equivalence to a trazodone-hydrochloride product.
Assessment sources
  1. Express Uspocoin exact label2023
  2. Express Uspocoin GE register2026
  3. EU Express Uspocoin market audit2026
  4. GB Express Uspocoin market audit2026
  5. FDA Express Uspocoin market audit2026
  6. Dog veterinary-visit RCT2022
  7. Dog road-travel trial2026
  8. Dog neurologic effects2022
  9. Dog QT study2025
  10. FDA trazodone veterinary status2025
  11. Trazodone class safety2026
  12. Cat veterinary-visit RCT2016
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Trazodone91.2 mg/tablet
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer (register)
Scientific Innovative Enterprise Astrafarm Ltd, Russia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 709, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 03 Aug 2027
Veterinary (National Food Agency)
In the register: ექსპრეს უსპოკოინი® ტაბლეტები
№ 000165
Verified on: 23 Oct 2026
 EU No
Verified on: 23 Oct 2026
 UK No
Verified on: 23 Oct 2026
 US No
Verified on: 23 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Dog
WeightSituational Anxiety · By mouth
9–12 kg 1/2 tablet
12–21 kg 1 tablet
21–30 kg 1 1/2 tablets
30–40 kg 2 tablets
  • Situational Anxiety · By mouth (once 60 minutes before the stressor; may repeat after 6-8 hours if needed): Give on an empty stomach or at least 2-4 hours after food. Do not use with hypersensitivity, liver/kidney dysfunction, cardiovascular disease or epilepsy, in pregnancy/lactation, or in newborn puppies. Sedation and impaired coordination can occur. For dogs over 40 kg the label starts with 2 tablets and adds half a tablet for each subsequent 10 kg; select that dose directly from the current label because it is a stepped, not continuous, rule.
Source:
Express Uspocoin label
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Express Uspocoin tablets - regulator-approved veterinary instruction
Rosselkhoznadzor-approved veterinary instruction, 2023
Active substance doses, with sources
Active substance Trazodone
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2–7.5 mg/kg
off-label
 Dog Sedation By mouth every 8-24 hours
MSD Vet Manual 2026
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Common Drugs Used to Treat Behavior Problems in Dogs (table)
MSD/Merck Veterinary Manual, 2026

Known Contraindications

  • Critical
    Hypersensitivity to the active substance or to any of the excipients.
    Sources: ANSM SPC
  • Critical
    Alcohol intoxication and intoxication with hypnotics.
    Sources: ANSM SPC
  • Critical
    Do not use trazodone during acute myocardial infarction or an equivalent unstable acute cardiac event. Overdose can cause tachycardia and hypotension.
    Sources: ANSM SPC
  • Warning
    Caution should be exercised in the event of hepatic impairment or severe renal impairment.
    Sources: ANSM SPC
  • Warning
    Use trazodone cautiously in severe renal impairment or hepatic impairment.
    Sources: ANSM SPC

Known Drug Interactions

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗